Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Fortress Biotech (FBIO) stocks in Canada

Learn how to easily invest in Fortress Biotech stocks.

Fortress Biotech is a biotechnology business based in the US. Fortress Biotech stocks (FBIO.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $3.39 – a decrease of 9.24% over the previous week. Fortress Biotech employs 111 staff and has a trailing 12-month revenue of around $64.3 million.

How to buy shares in Fortress Biotech

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – FBIO – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Is it a good time to buy Fortress Biotech stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

How has Coronavirus impacted Fortress Biotech's stock price?

Since the stock market crash in March caused by coronavirus, Fortress Biotech's stock price has had significant negative movement.

Its last market close was $2.16, which is 20.30% down on its pre-crash value of $2.71 and 107.69% up on the lowest point reached during the March crash when the stocks fell as low as $1.04.

If you had bought $1,000 worth of Fortress Biotech stocks at the start of February 2020, those stocks would have been worth $569.51 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $968.61.

Fortress Biotech stock price (NASDAQ:FBIO)

Use our graph to track the performance of FBIO stocks over time.

Fortress Biotech shares at a glance

Information last updated 2022-01-17.
Latest market close$2.16
52-week range$2.21 - $6.10
50-day moving average $2.79
200-day moving average $3.36
Wall St. target price$10.33
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.48

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.

Compare up to 4 providers

Online stock trading

Fortress Biotech price performance over time

Historical closes compared with the close of $2.16 from 2022-01-18

1 week (2022-01-08) N/A
1 month (2021-12-17) -14.29%
3 months (2021-10-19) -28.71%
6 months (2021-07-19) -31.21%
1 year (2021-01-19) -40.00%
2 years (2020-01-17) -16.28%
3 years (2019-01-18) 87.83%
5 years (2017-01-19) 2.27

Fortress Biotech financials

Revenue TTM $64.3 million
Gross profit TTM $31 million
Return on assets TTM -24.35%
Return on equity TTM -60.12%
Profit margin -59.81%
Book value $0.94
Market capitalisation $230.1 million

TTM: trailing 12 months

Fortress Biotech share dividends

We're not expecting Fortress Biotech to pay a dividend over the next 12 months.

Fortress Biotech share price volatility

Over the last 12 months, Fortress Biotech's shares have ranged in value from as little as $2.21 up to $6.1. A popular way to gauge a stock's volatility is its "beta".

FBIO.US volatility(beta: 2.26)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Fortress Biotech's is 2.258. This would suggest that Fortress Biotech's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Fortress Biotech overview

Fortress Biotech, Inc. , a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies.

Stocks similar to Fortress Biotech

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site